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The detection of infectious pathogens is essential for the induction of antimicrobial immune responses. The
innate immune system detects a wide array of microbes using a limited set of pattern-recognition receptors
(PRRs). One family of PRRs with a central role in innate immunity are the Toll-like receptors (TLRs). Upon
ligation, these receptors initiate signaling pathways culminating in the release of pro-inflammatory cytokines
and/or type I interferons (IFN-I). In recent years, it has become evident that the specific subcellular location
and timing of TLR activation affect signaling outcome. The subtlety of this signaling has led to a growing
demand for chemical tools that provide the ability to conditionally control TLR activation. In this review,
we survey current models for TLR signaling in time and space, discuss how chemical tools have contributed
to our understanding of TLR ligands, and describe how they can aid further elucidation of the dynamic
aspects of TLR signaling.Innate Immune Signaling via Toll-like Receptors
Host defense against infection critically depends on the innate
immune system, which recognizes invading pathogens through
pattern-recognition receptors (PRRs). PRRs sense pathogens
through the recognition of conserved pathogen-associated mo-
lecular patterns (PAMPs) (Janeway and Medzhitov, 2002) and
they recognize inappropriate cell death through the detection
of danger-associated molecular patterns (McCarthy et al.,
2014). Toll-like receptors (TLRs) are a key family of PRRs.
Binding of conservedmicrobial structures, such as cell wall com-
ponents, to TLRs results in the induction of a variety of signaling
pathways. The outcome of these signaling events is the induc-
tion of pro-inflammatory cytokines, which act as general mobiliz-
ers of innate and adaptive immune cells, and/or type I interferons
(IFN-I), inducing processes that directly inhibit microbial replica-
tion. Together these effector molecules lead to the immediate
mobilization of both innate and adaptive immune components
to appropriately combat the infectious agent. Recent develop-
ments in the study of TLR signaling have shed light on the com-
plex orchestration of signaling events leading to IFN-I or pro-in-
flammatory cytokine production. This review focuses on this
dynamic picture of TLR signaling as well as the chemical re-
agents currently developed to further elucidate temporal and
spatial parameters in this pathway.
The mammalian TLR family consists of 13 members, of which
TLR1 to TLR9 are conserved between humans and mice (Rehli,
2002). Due to a retroviral insertion, mouse TLR10 is not func-
tional, whereas the human genome has lost TLR11, TLR12,
and TLR13. All TLR family members share a common structure,
consisting of anN-terminal ectodomain, a single transmembrane
domain, and a C-terminal cytosolic Toll-interleukin-1 receptor
(TIR) domain (Botos et al., 2011). The ectodomain contains
multiple leucine-rich repeats that are involved in ligand re-
cognition, whereas the TIR domain mediates recruitment ofTIR domain-containing signaling proteins (Jenkins and Mansell,
2010). TLRs may be classified based on their predominant
cellular localization in the absence of stimulation: TLR1, TLR2,
TLR4, TLR5, and TLR6mainly reside on the cell surface, whereas
TLR3, TLR7, TLR8, andTLR9are retained intracellularly (Figure 1)
(McGettrick and O’Neill, 2010).
Upon activation, TLRs dimerize (Botos et al., 2011). Most TLRs
form homodimers, except for TLR2 which preferentially forms
heterodimers with TLR1 or TLR6 (Kang et al., 2009; Jin et al.,
2007). This initiates distinct signal transduction pathways that
culminate in the transcription of genes important for host de-
fense, including those coding for pro-inflammatory cytokines
(e.g., tumor necrosis factor alpha [TNF-a], interleukin-6 [IL-6],
IL-8) and type I interferons (e.g., IFN-a and IFN-b) (Tseng et al.,
2010). Prototypically, the induction of pro-inflammatory cyto-
kines is mediated through the transcription factor nuclear factor
kB (NF-kB) (Li and Verma, 2002), whereas IFN-I transcription is
induced by activation of members of the interferon regulatory
transcription factor (IRF) family (Honda and Taniguchi, 2006).
Pro-inflammatory cytokines and chemokines induce maturation
of innate immune cells and help orchestrate subsequent adap-
tive immune responses. IFN-I interacts with the IFN-a/b receptor
in an autocrine and paracrine manner, inducing the transcription
of hundreds of IFN-stimulated genes (ISGs). Many ISGs harbor
direct antimicrobial activities, particularly against viruses.
From the plasmamembrane, TLRs survey cell surroundings for
the presence of pathogens. For example, surface TLR2 and TLR4
can detect the bacterial cell wall components, peptidoglycans
and glycolipids, from Gram-positive, and lipopolysaccharide
(LPS) from Gram-negative bacteria, respectively (Mancini et al.,
2014). TLR2 also detects viral structural proteins, despite their
general variability (Barton, 2007; Thompson and Iwasaki, 2008).
TLR5 detects flagellin from a wide range of bacterial species.
Flagellin contains highly conserved sequence stretches criticalCell Chemical Biology 24, July 20, 2017 ª 2017 Elsevier Ltd. 801
Figure 1. TLRs Can Be Classified Based on Their Predominant
Cellular Localization in the Absence of Stimulation
TLR1, TLR2, TLR4, TLR5, and TLR6 mainly reside at the cell surface, whereas
TLR3, TLR7, TLR8, and TLR9 are retained intracellularly. Examples of proto-
typical ligands are indicated.
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facile formation of escape mutants (Hayashi et al., 2001).
The intracellular TLRs (TLR3, TLR7, TLR8, and TLR9) sense
PAMPs of pathogens that have entered cells. Viruses and bac-
teria typically enter cells through endocytosis or phagocytosis,
and intracellular TLRs signal solely from vesicles along this
pathway. Each TLR engages a different type of microbial nucleic
acid (NA): TLR3 recognizes viral double-stranded RNA (Alexo-
poulou et al., 2001), TLR7 and TLR8 engage viral single-stranded
RNA (Lund et al., 2004; Heil et al., 2004), and TLR9 recognizes
unmethylated DNA containing CpG motifs (Hemmi et al., 2000).
Restricting the activation of NA-sensing TLRs to endolysosomal
vesicles is believed to serve as a mechanism to prevent the
recognition of host-derived NA (Lee and Barton, 2014).
Recent studies have revealed additional layers of complexity
related to the signaling of TLRs. For example, surface-expressed
TLRs were shown to also be capable of signaling from intra-
cellular vesicles (McGettrick and O’Neill, 2010). Furthermore,
this signaling resulted in the production of different cytokine-
expression profiles (Tan and Kagan, 2016). The finding that
TLR4 induces NF-kB and IRF activation from different locations
within the cell was the first example of how spatial context
affects TLR signaling output (Figure 4A). This is also the case
for the intracellular TLRs. Data suggest that they too signal differ-
ently from different intracellular compartments.
In this review, we discuss this emerging view that signal trans-
duction via TLRs is orchestrated in space and timewithin cells, to
induce a response of appropriate quality (specificity, amplitude,
and duration). The importance of understanding the regulatory
mechanisms is underscored by the fact that activation of mislo-
calized TLRs is implicated in recurrent viral infections (Blasius
et al., 2010) and autoimmune diseases (Barton et al., 2006).802 Cell Chemical Biology 24, July 20, 2017Furthermore, we discuss the development of new reagents
that allow the study of TLR signaling dynamics and can
contribute to the delineation of spatial and temporal components
of their signaling pathways.
Synthetic TLR Ligands
Chemistshavemadeamajor contribution to theelucidationofTLR
function by developing selective synthetic TLR ligands (Table 1).
For over a hundred years, it has been known that mixtures of
attenuated bacteria, such as Coley’s toxin, aid in the treatment
of diseases such as cancer, through the induction of a general
pro-inflammatory state (Hennessy et al., 2010). Yet, even after
the identification of TLRs and other PRRs, it proved difficult to
elucidate which receptor was responsible for detecting which
PAMP. Strategies to extract natural ligands from complex biolog-
ical samples helped in the discrimination of natural ligands for
PRRs. The yeast cellwall extract zymosan is anexample of a com-
plex mixture, capable of activating both TLR2 and the b-glucan-
binding receptor Dectin-1. Activation of TLR2 was thought to
rely on lipopeptides in this extract. This was confirmed by extract-
ing the lipopeptides using organic solvents, leaving a b-glucan
preparation incapableof activatingTLR2 (Ikedaet al., 2008).Char-
acterizationof natural ligands is further complicatedbymacromol-
ecules that can engage multiple PRRs. A recent report from the
Kawasaki laboratory showed that certain types of bacterial LPSs
serve as dual PRR ligands (Wittmann et al., 2016). The lipid A
portion of the LPS engages TLR4 via interactionwithmultiple fatty
acid tails that are pendant fromadi-glucosamine sugar.Additional
sugars attached to the glucosaminyl-core can ligate to a second
unrelated PRR, Dectin-2, through classical lectin-glycan interac-
tions. This second interaction appears to modulate signaling
from the lipid A/TLR4 interaction, thereby altering the overall
immunological outcome. This Dectin-2 activation could be pre-
vented by enzymatic removal of the extended glycan.
The study of TLR ligands has long been hampered by such
complicating factors relating to PRR crosstalk. The elucidation
of specific ligand-receptor pairs was difficult due to the absence
of pure, well-defined ligands. This is where chemists made their
first valuable contribution to the field: by developing defined syn-
thetic ligands, specific TLRs could be activated selectively. This
has also facilitated regulatory approval for their inclusion in vac-
cines and pro-inflammatory therapies. With great success, as
dozens of synthetic TLR ligands are currently in clinical trials
for the treatment of cancer, viral and bacterial infections, allergy,
asthma, and autoimmune diseases (Hennessy et al., 2010). To
date, two synthetic ligands have been approved by the FDA for
clinical use: imiquimod (TLR7/8) is used as a 5% cream for
human papillomavirus (HPV)-induced genital warts, actinic kera-
tosis, and superficial basal cell carcinoma, and monophosphoryl
lipid A (TLR4) is used as a vaccine adjuvant for HPV type 16 and
type 18 (HPV16 and HPV18) (Vacchelli et al., 2012).
A great example of how chemistry, in combination with struc-
tural biology, has helped delineate TLR ligand interactions, is
that of TLR2 binding its synthetic lipopeptide ligands. Pam3CSK4
(1) (Figure 2) was among the first discovered lipopeptides that
acts as a lipoprotein mimic in activating TLR2/1 signaling path-
ways (Aliprantis et al., 1999) (Table 1). Pam3CSK4 is still a rather
large molecule, containing three highly lipophilic tails and six
amino acids. Via multiple iterations, this ligand has been
Table 1. Discovery of TLR Ligands Used for Caging Strategies
Toll-Like Receptor Ligand(s) Mechanism(s) of Action References
TLR2 short synthetic lipopeptides with a palmitylated
N-terminal amino acid: Pam3CSK4 and
Pam2CSK4
mimic the immunostimulatory effect of bacterial
lipopeptides
Norgard et al. (1996)
Hoffmann et al. (1988)
Aliprantis et al. (1999)
TLR4 non-lipid-like molecules structurally unrelated
to known natural ligands: pyrimido[5,4-b]-
indoles
likely dock in the LPS-binding pocket of TLR4 Chan et al. (2013)
TLR7 and TLR8 imidazoquinolines resembling the nucleoside
guanosine: resiquimod (TLR7 and TLR8) and
imiquimod (TLR7)
bind to ligand binding site, activate TLR7 and/or
TLR8, and induce IFN-a in various cell types
Hemmi et al. (2002)
Jurk et al. (2002)
Shibata et al. (2016)
Tanji et al. (2015)
TLR9 synthetic phosphorothioate-stabilized
oligodeoxynucleotides (ODNs) with varying the
number and location of CpG dimers and their
overall nucleotide sequence
bind to TLR9, a sensor of CpGDNA, and lead to
immunostimulatory effect mimicking effects of
bacterial DNA
Krieg et al. (1995)
Hemmi et al. (2000)
To date chemical caging strategies have been reported for five different synthetic TLR ligands. These ligands were discovered in various ways. Some
mimic PAMPs present in pathogens, while others are structurally unrelated to natural ligands.
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nanomolar activity. The palmitoyl tail present on the N terminus
of the cysteine proved to be a dispensable moiety for TLR2 acti-
vation. Removal of this lipophilic tail resulted in the highly potent
Pam2CSK4 (M€uhlradt et al., 1998) (2) and introduced a prefer-
ence for TLR2/6 heterodimerization (Takeuchi et al., 2002). The
preference of TLR2 for either TLR1 or TLR6 heterodimerization
is best explained with the help of the crystal structures of
ligand-boundmouse TLR2/6 (Figure 3) and human TLR2/1 heter-
odimers (Jin et al., 2007). The two palmitoyl tails of the TLR ligand
present on the glycerol moiety interact with TLR2 by strongly
binding in a hydrophobic pocket, the volume of this pocket being
15% larger than theoretically necessary for binding. This surplus
of space allows for flexibility in the lipid moieties when modifying
the chemical structure (Buwitt-Beckmann et al., 2005). Dimeriza-
tion of the now ligand-bound TLR2 can either occur with TLR1 or
TLR6, depending on the presence of a lipid moiety on the N ter-
minus of the cysteine. In the case of Pam3CSK4, the amide-
bound palmitoyl tail is guided into a channel present in TLR1
by a hydrophobic wall formed by residues F312, F314, I319,
and Y320, facilitating dimerization. In the Pam2CSK4 construct,
however, the amide-bound lipid tail is lacking and this initiates
a structural rearrangement of the hydrophobic wall. The corre-
sponding residues of this wall in TLR6 move inside the pocket
by means of hydrophobic interaction. This, in turn, pushes
F317 out of the lipid channel, shifting the LRR11 loop in such a
way that F319 can now engage in a hydrogen bond with the
amide connecting the serine with the cysteine of the Pam2CSK4
construct. This hydrogen bond is absent in the Pam3CSK4-
bound TLR2/1 crystal structure (Jin et al., 2007). Finally, TLR2/
6 dimerization by Pam3CSK4 is prevented due to the hydro-
phobic channel on TLR6 being blocked by bulky side chains pre-
sent on F343 and F365. Removing the bulky aromatic side chains
through mutagenesis in TLR6 led to TLR2/6 dimerization by
Pam3CSK4.
Using Pam2CSK4 as a benchmark, several structure-activity
relationship (SAR) studies have been carried out (Figures 2 and
3B). The Cys-Ser lipodipeptide (3) was identified as the minimal
structure necessary for TLR2 activation (Prass et al., 1987).Removal of serine yields an inactive Cys-OH monomer (Bessler
et al., 1985). Replacing the amino acid by glycine (4), for
instance, has little impact on the activity (Takeuchi et al., 2002).
The stereocenter in the glycerol derivative cannot be inverted,
as the absolute S-configuration shows complete abrogation of
activity (5) (Metzger et al., 1991; Takeuchi et al., 2000). The
configuration of the stereocenter on the dipeptide unit is not of
absolute importance, as long as the carbonyl of the Cys-Ser
amide bond can engage in H-bonding in the binding pocket of
TLR2 (Wu et al., 2010b). Replacement of the thioether with an
ether bridge (6) reduced the activity by eight orders of magnitude
(Wu et al., 2010b), while replacement with a selenoether bridge
(7) caused no difference in activity when compared with com-
pound (3) (Agnihotri et al., 2011). Removal of a palmitoyl ester
and a methylene yielded the simpler monoacylated PamCS
methyl ester lipopeptide (8). This modification completely abro-
gated its activity as a murine TLR2 activator, while retaining
the capacity to induce human TLR2 activation (Agnihotri et al.,
2011). Compared with compound (3), compound (8) is both
easier to synthesize and more water soluble (Agnihotri et al.,
2011). Although acetylation of the cysteine amine (9) led to only
a small enhancement of the agonistic activity on the receptor it-
self, the resulting cytokine production (after NF-kB nuclear trans-
location) was far greater at equal doses. The potency of this
PamCS (9) approached that of Pam2CS (3) (Salunke et al., 2012).
Although this methodology of finding superior ligands proved
fruitful, it remains a process of trial and error. The recent spate of
crystal structures of ligand-engaged TLRs and computer
modeling studies will likely contribute greatly to the design of
more selective, simpler, and more potent ligands (Botos
et al., 2011).
Using Synthetic Ligands to Elucidate TLR Signaling
Well-defined and pure synthetic TLR ligands are used to study
members of the TLR family in a broad spectrum of experimental
settings and cell types, largely focusing on cell lines. Since good
antibodies against many TLRs are lacking, recombinantly
tagged TLR proteins have been introduced in cell lines, to allow
detection with antibodies directed against the tag. FluorescentCell Chemical Biology 24, July 20, 2017 803
Figure 2. Structures and Relative Activities of Synthetic TLR2
Ligands
Depicted are TLR2 agonists that have resulted from several SAR studies.
These studies aimed to simplify the ligand structure, while maintaining their
activity and increasing their solubility in aqueous medium. Highlighted in red
are alterations applied within the molecule. Relative activities (R.A.) are based
on EC50 and IC50 values as reported in the biological evaluation of the
respective compound in the cited study are 1, 2 > 3, 4, 7, 9 > 8 [ 6; relative
activity of 5 is unknown. First reports of structures: 1 (Aliprantis et al., 1999); 2
(M€uhlradt et al., 1998); 3 (Farhat et al., 2008); 4, 7, 8 (Agnihotri et al., 2011); 5
(Takeuchi et al., 2000); 6 (Wu et al., 2010b); 9 (Salunke et al., 2012).
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living cells. It is, however, difficult to assess if the tags affect
receptor trafficking and function. The delicacy of TLR signaling
results in cell type-specific outcomes, and therefore immune
responses induced by TLR activation should be addressed in
their native cellular context (Wu et al., 2010a). A prominent
example of cell type-specific outcomes of TLR activation is
that of two subsets of dendritic cells (DCs). While a minor subset
of DCs, the plasmacytoid DCs (pDCs), produces a large amount
of IFN-I in response to TLR7 and TLR9 ligands, the conventional
DCs (cDCs) mainly produce pro-inflammatory cytokines (Reizis
et al., 2011; O’Keeffe et al., 2005).
In the above-mentioned settings, selective synthetic TLR
ligands are frequently used to study receptor function. Detailed
characterization of the synthetic ligands is of utmost importance,
as small changes in ligand structures can affect the interaction
with TLRs. Caution should be taken when translating functional
results obtained with synthetic TLR ligands to a more natural
mode of activation. As an example, small-molecule imidazoqui-
noline ligands (Table 1) and natural single-stranded RNA ligands
occupy different binding pockets within TLR7 and TLR8, thereby
inducing different functional outcomes (Zhang et al., 2016b;
Colak et al., 2014).
In the past, research has primarily focused on TLR7. Differ-
ences in themolecular basis for ligand recognition and activation804 Cell Chemical Biology 24, July 20, 2017between TLR7 and TLR8 have recently led to a growing popu-
larity for studying TLR8 function. This has culminated in a crystal
structure of the imidazoquinoline ligand resiquimod in complex
with human TLR8 (Tanji et al., 2013). From this structure, the
mechanism by which resiquimod activates TLR8, and possibly
TLR7, has been resolved. In solution, recombinant TLR8 pro-
teins exist as dimers in an inactive form. Ligand binding induces
a set of conformational changes leading to shortening of the gap
between the C termini from 53 to 30 Å. This proximity allows
dimerization of the TIR domains, thus leading to downstream
signaling. Per dimer, two small-molecule ligands are able to
bind due to a 2-fold symmetry. For the ligand resiquimod, the
most notable hydrophilic interaction is with the carboxylate func-
tionality in the side chain of an aspartic acid residue, which forms
hydrogen bonds with the amidine functionality of the ligand in
almost perfect geometry.
In recent years, chemists have started to develop more
advanced chemical tools based on synthetic TLR ligands. For
example, bi- and trifunctional TLR ligands have been developed.
These ligands induce ligation of multiple TLRs in near proximity
on the plasmamembrane (Tom et al., 2015), and signaling output
proved to be cumulative (Ryu et al., 2016). Recent data suggest
that not only the cell type, but also the place and time of TLR acti-
vation within cells, critically affects signaling outcome. The
spatiotemporal aspects of TLR signaling and novel chemical
tools that may help delineate underlying regulatory mechanisms,
are discussed below in more detail.
Surface-Expressed TLRs Induce NF-kB and IRF
Activation from Different Locations within Cells
The first example of spatiotemporal control came from the study
of TLR4 (Figure 4A). The signaling events leading to induction of
pro-inflammatory cytokines originate from TLR4 ligation at the
plasma membrane. Upon engagement of a ligand at the cell
surface, TLR4 dimers recruit the sorting adaptor TIR domain-
containing adaptor protein (TIRAP) and the signaling adaptor
myeloid differentiation primary response 88 (MyD88) (O’Neill
and Bowie, 2007). These adaptors recruit downstream signaling
molecules, forming an extensive signaling platform, also called
the Myddosome (Motshwene et al., 2009). A coordinated series
of phosphorylation and ubiquitination events, involving the E3
ubiquitin ligase TRAF6, ultimately causes the release of cytosolic
NF-kB from its inhibitor, IkBa (Wang et al., 2001). NF-kB then
translocates into the nucleus to induce transcription of pro-
inflammatory cytokine genes.
The production of IFN-I following TLR4 ligation is mediated via
a second signaling pathway that originates from endosomes.
TLR4’s capacity to signal from endosomes was identified using
chemical inhibitors of clathrin-mediated endocytosis, which
selectively inhibited the synthesis of IFN-I, but not pro-inflamma-
tory cytokines (Kagan et al., 2008; Tatematsu et al., 2016). These
inhibitors included chlorpromazine and dynasore. Chlorproma-
zine is a cationic amphiphilic drug that inhibits the formation of
clathrin-coated pits, the sites at which the plasma membrane in-
vaginates (Wang et al., 1993). Dynasore instead acts on the
GTPase dynamin, which regulates the scission of membrane in-
vaginations to form early endosomes (Macia et al., 2006).
Compared with cell surface TLR4 complexes, endosomal TLR4
complexes recruit a different set of adaptor proteins, comprising
Figure 3. Ligand Binding of Pam2CSK4 to TLR2/6
(A) Surface rendering of the crystal structure of Pam2CSK4-bound TLR2/6 heterodimers (Kang et al., 2009). Key interacting residues are highlighted.
(B) Residues interacting with Pam2CSK4. Depicted in orange are TLR2 residues, depicted in blue a TLR6 residue. Green dashed lines represent potential
hydrogen bonds with calculated distances (in Å). The four C-terminal lysine residues of the ligand have little to no interaction with the TLR2/6 complex. The two
palmitoyl tails fit inside a hydrophobic pocket present on TLR2.
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containing adaptor-inducing IFN-b (TRIF) (Yamamoto et al.,
2003a, 2003b). TRAM and TRIF function as sorting and signaling
adaptors, respectively. Subsequent recruitment of various
signaling components, including TRAF3, culminates in the acti-
vation and nuclear translocation of the transcription factor
IRF3. This in turn induces transcription of genes encoding IFN-I.
The spatially separated signaling pathways activating NF-kB
and IRF3 are now thought to occur sequentially (Kagan et al.,
2008). Switching from an NF-kB-activating pathway from the
cell surface to an IRF3-activating pathway from endolysosomal
vesicles is mediated through recruitment of TRAM. Prior to
TLR4 stimulation, TRAMbindsmembrane lipids of the trans-Golgi
network (TGN) and the plasma membrane through a bipartite
N-terminal localization motif, which consists of a myristoylation
motif followed by a polybasic domain (Rowe et al., 2006). Upon
LPS stimulation, the TGN-localized pool of TRAM translocates
to TLR4-containing endosomes (Klein et al., 2015). Here, TRAM
displaces TIRAP from the TIR domain of TLR4, effectuating the
switch from an NF-kB-dominated pathway to an IRF-dominated
pathway (Kagan et al., 2008). It remains to be established what
triggers TRAM displacement from the TGN and why TRAM
does not engage TLR4 at the plasma membrane.
Translocation of the ligand-engaged TLR4 molecules from
the cell surface to endosomes is not induced by the receptor
itself or the downstream signaling cascade, but is instead regu-
lated by accessory proteins, such as MD-2 and CD14. These
accessory proteins were initially linked to TLR4 signaling for
facilitating the transfer of LPS to TLR4 (Shimazu et al., 1999;
da Silva Correia et al., 2001). Later, an additional role for CD14
in orchestrating TLR4 internalization was identified. First, CD14
targets TLR4 to lipid rafts on the cell surface, where the receptor
signals through TIRAP/MyD88 (Triantafilou et al., 2002). Second,
CD14 enhances endocytosis of TLR4 (Zanoni et al., 2011), re-
sulting in a shift toward IFN-I signaling via TRAM/TRIF. The dy-
namics of these processes are difficult to study using standardapproaches, but here ‘‘state-of-the-art’’ microscopes have
enabled mobility studies of TLR4 and its accessory and adaptor
proteins through fluorescence recovery after photo-bleaching
experiments (Klein et al., 2015).
Since the signaling output of TLR4 is tightly coupled to its
spatial context, general cell biological processes involved in
endocytosis and protein trafficking will affect TLR signaling
output. To date, a number of proteins involved in endocytosis
has been shown to facilitate TLR4 internalization. These factors
include p120-catenin, the GTPase ADP ribosylation factor 6
(ARF6), Annexin A2 (AxnA2), and the integrin CD11b (Yang
et al., 2014; Van Acker et al., 2014; Ling et al., 2014; Zhang
et al., 2015). Depletion of any of these factors abrogates LPS-
induced IFN-I secretion, highlighting their importance. Yet, their
exact mechanisms of action remain to be resolved. AxnA2 and
p120 reduce TLR4 surface levels, thereby skewing TLR4
signaling away from the MyD88-driven production of pro-inflam-
matory cytokines (e.g., TNF-a, IL-6, IL-1b) in LPS-treated murine
macrophages (Yang et al., 2014; Zhang et al., 2015). This
indicates that the process of TLR4 internalization acts as a
double-edged sword: it both dampens the pro-inflammatory
response and enhances IFN-I secretion.
The concept that a surface-expressed TLR is internalized into
endosomes from which it induces signals leading to IFN-I secre-
tion also applies to TLR2 (Figure 4A). TLR2 was long considered
the archetypical cell surface receptor for inducing potent pro-in-
flammatory responses upon sensing acetylated lipoproteins. For
this reason, small-molecule TLR2 ligands were rapidly devel-
oped to be used as pro-inflammatory stimulants in vaccines,
as described above. The discovery that TLR2 induced IFN-b pro-
duction inmurine inflammatorymonocytes upon stimulation with
inactivated murine cytomegalovirus and vaccinia virus (Barbalat
et al., 2009) shed new light on additional effector functions of this
receptor. Internalization of TLR2 was essential for IFN-I pro-
duction, but not for the secretion of pro-inflammatory cytokines.
This was concluded from experiments in which endocytosis orCell Chemical Biology 24, July 20, 2017 805
Figure 4. TLRs Induce Distinct Signaling Cascades Depending on Their (sub)Cellular Localization
(A) At the cell surface, ligand-bound TLR4 dimers assemble a signaling complex by engaging TIRAP and MyD88. This induces a signaling cascade that results in
the production of pro-inflammatory cytokines via NF-kB. Internalized TLR4 dimers are retained in endosomes, where they trigger signal transduction via TRAM
and TRIF, leading to the activation of IRF3 and induction of IFN-I. Although less well described, there are indications that TLR2/1 and TLR2/6 heterodimers can
also induce the activation of NF-kB and IRFs from the cell surface and endosomes, respectively.
(B) The signaling cascades induced by TLR9 to activate NF-kB or IRF7 both involve TIRAP and MyD88, but originate from distinct endosomal populations. From
early endosomes (EE), TLR9 induces NF-kB activation, resulting in the production of pro-inflammatory cytokines. In contrast, TLR9 activation from late endo-
somes (LE) and/or lysosome-related organelles (LRO) results in IRF7-dependent production of IFN-I.
Dashed lines represent trafficking pathways; solid lines represent signaling pathways.
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chloroquine, respectively. Intriguingly, IFN-I was not induced in
inflammatory monocytes with low doses of synthetic TLR2
ligands. In a later report, IFN-I production by bone marrow-
derivedmacrophages (BMDMs) was observed at higher concen-
trations of synthetic TLR2 ligands (Dietrich et al., 2010). An IFN-I
signaling pathway was induced, both by stimuli that mimic lipo-
proteins (Pam2CSK4, Pam3CSK4, and FSL-1), and by the glyco-
lipid agonist lipoteichoic acid. The capacity of TLR2 to induce
IFN-I therefore does not appear to rely on the nature of the ligand
by which it is activated and is likely operational downstream of
TLR2/1 and TLR2/6 heterodimer complexes. To prove this,
knockout studies would be required, as most cells express
TLR1 and TLR6. Since the initial observation of TLR2-induced
IFN-I production, there has been a growing body of evidence
for a model where TLR2, like TLR4, assembles NF-kB-activating
signaling platforms at the plasma membrane and IRF-activating
platforms at endosomal vesicles.
In contrast to TLR4, bifurcation of TLR2 signaling events has
only been known for a few years. Therefore, little is known yet
about the factors that regulate the spatiotemporal aspects of
TLR2 signaling. So far, studies have primarily focused on identi-
fying which adaptor proteins are recruited by TLR2 at the plasma806 Cell Chemical Biology 24, July 20, 2017membrane and at vesicles of the endolysosomal system. It is
worthmentioning that these studies havemainly been performed
using mouse cells, and a recent report suggests certain mecha-
nistic aspects of TLR2 signaling may vary between mice and
humans (Brandt et al., 2013). The signaling platform assembled
by TLR2 at the cell surface resembles that of TLR4. Both recep-
tors employ the adaptor proteins TIRAP and MyD88 to induce
signals that activate NF-kB via TRAF6, leading to the production
of pro-inflammatory cytokines (Yamamoto et al., 2002). Of note,
TIRAP is dispensable at high doses of TLR2 ligand (Kenny et al.,
2009), which possibly allows sufficient amounts of MyD88 to
couple to TLR2 in the absence of TIRAP.
In endosomal vesicles, TLR2 and TLR4 employ different sets of
adaptors. In addition, TLR2 appears to affect a broader range of
genes than TLR4, with IRF3 and also IRF7 activated upon stimu-
lation (Barbalat et al., 2009). Unlike TLR4, the IFN-I inducing
signaling platform assembled by TLR2 critically depends on
MyD88 (Barbalat et al., 2009; Dietrich et al., 2010). TRAM is part
of endosomal TLR2 signaling platforms, interacting both with
TLR2 and MyD88 (Stack et al., 2014). Its importance for signal
transduction follows from cells expressing a TRAM mutant inca-
pable of associating with endosomes and immortalized TRAM-
deficient BMDMs: both cell types are thwarted in IFN-I production
Figure 5. Photocaged Ligands and
Uncaging by Photoirradiation
(A) The TLR2 ligand Pam2CSK4K(FAM) protected
with NPPOC (blue) at the N terminus (red).
(B) A typical uncaging reaction of an ortho-nitro-
benzyl-derivative initiated by photoirradiation.
(C) A pyrimido[5,4-b]-indole-based TLR4 ligand
protected with NVOC (blue) on the amine that is
critical for its activity (red).
(D) The two-photon excitation compatible group
NBDF (blue) can be applied to cage agonists such
as IP3.
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Whether TRIF, the signaling adaptor recruited by TRAM in case of
TLR4 stimulation, is also required for signaling by endosomal
TLR2 is more controversial. Nilsen et al. (2015) observed a
partially impaired induction of CCL5, CCL4, and IFN-b by TLR2-
stimulated TRIF-deficient BMDMs. Overexpressed fluorescently
labeled TLR2 and TRIF co-localized at endosomal vesicles in
HEK293 cells (Nilsen et al., 2015). In contrast, Stack et al. (2014)
did not detect a TRIF-dependence in the output of IFN-I by
BMDMs. The precise involvement of TRIF regarding endosomal
TLR2 signaling, therefore, remains to be established.
In summary, both TLR4 and TLR2 assemble distinct signaling
platforms at the plasma membrane and endosomal vesicles,
which in turn induce the activation of NF-kB and members of
the IRF family, respectively. Numerous factors involved in protein
trafficking and accessory proteins of TLR4 have been identified
that control the translocation of TLR4 and its adaptors to endo-
somal vesicles. Controlled translocation of TLR4 proved to be
critical for shaping the induced innate response. It is likely that
similar processes regulate TLR2-induced responses, which will
need to be elucidated in future research. Potential candidates
include accessory molecules for TLR2 ligand binding, such as
CD36, CD14, and mannose binding lectin (Hoebe et al., 2005;
Manukyan et al., 2005). The biological implications of inducing
distinct signaling occurring from different cellular locations are
not yet fully known. Perhaps, this might have evolved to fine-
tune the innate immune response depending on the pathogen.
The kinetics of the microbe-induced trafficking of the TLRs
would allow the cell to induce a balanced response to the
pathogen (Tan and Kagan, 2016). This would explain how the
promiscuous receptor TLR2 can elicit tailored responses to a
wide variety of natural ligands.
Knowledge of the dynamics by which TLR2 and TLR4 are
regulated will aid in unraveling the spatiotemporal complexity
of signaling by these receptors. This can only be investigated
to a certain extent with classical synthetic TLR ligands because
they are limited to bulk activation of cells. Next, we discuss new
chemical tools that allow conditional control of TLR activation,
which could prove very useful to study TLR signaling dynamics
within individual cells.C
Photocaged TLR2 and TLR4 Ligands
as Tools to Study Signaling
Dynamics
A new class of reagents that may aid in
elucidating the spatiotemporal complexity
of TLR signaling dynamics are photoc-aged TLR ligands. Photocaging (the protection of ligands to a
non-binding state using photolabile protecting groups) has
been performed on, among others, TLR2 and TLR4 ligands,
yielding tools by which TLR activation can be conditionally
controlled using light.
The aforementioned crystal structure (Figure 3A) and SAR
studies of the TLR2 ligand Pam2CSK4 (2) indicated that a substi-
tution at the N terminus of the cysteine renders the ligand inac-
tive (Wu et al., 2010b). Using this information, a photocaged
TLR2 ligand was developed (Mancini et al., 2015). The caging
strategy here relies on preventing the hydrogen bond between
F319 and the amide bond of the construct to be formed
(Figure 3B). This may be facilitated by pure steric hindrance of
the protecting group present on the cysteine amine. However,
the protecting group used is also a hydrophobic moiety capable
of interacting with the hydrophobic wall, potentially preventing
the LRR11 loop shift from occurring. This can lead to an absence
of proximity of F319, thus negating the hydrogen bond forma-
tion. Using this rationale, a 2-(2-nitrophenyl)propyloxycarbonyl
(NPPOC) group was introduced on the N terminus, indeed
rendering the ligand inactive (Figure 5A). NPPOC is an ortho-
nitrobenzyl (NB)-derived photocleavable group, which un-
dergoes UV-mediated intramolecular hydrogen atom transfer
onto the nitro-group leading to its elimination upon irradiation
with UV light (Woll et al., 2007) (Figure 5B). To be able to visualize
the photocaged ligand, the fluorophore carboxyfluorescein
(FAM) was incorporated. FAM was attached to the terminal
lysine residue, because the lysine residues of Pam2CSK4 do
not interact with TLR2 or TLR6 (Prass et al., 1987). Incubation
of TLR2-expressing cells with the photocaged TLR2 ligand re-
sulted in a pre-existing pool of ligand-bound TLR2 molecules,
without inducing their activation. The ligand was distributed on
the plasma membrane and in endosomes, consistent with
TLR2 trafficking. Subsequent UV irradiation induced nuclear
translocation of p65, a subunit of NF-kB, in the fibroblast cell
line 3t3 and release of TNF-a from BMDMs indicating TLR2
activation.
In the case of TLR4, activation can be controlled using a pho-
tocaged ligand based on the synthetic agonist pyrimido[5,4-b]-
indole. SAR studies indicated that substitutions on the indoleell Chemical Biology 24, July 20, 2017 807
Figure 6. Ligands for NA-Sensing TLRs Protected with Photocages
(A) The TLR7 and TLR8 dual agonist resiquimod protected with NPPOC (blue)
on the amine that is critical for its activity (red).
(B) A photocaged thymidine residue residing in a phosphorothioate-linked
CpG oligodeoxynucleotide. The photocage nitropiperonyloxymethyl (blue) on
the nitrogen (indicated in red) prevents TLR9 activation.
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ligand was synthesized by alkylating the critical indole nitrogen
with a nitroveratryloxycarbonyl (NVOC)-group (Stutts and
Esser-Kahn, 2015) (Figure 5C). Like NPPOC, NVOC is also
cleaved upon UV irradiation. Using UV/Vis spectroscopy and
high-performance liquid chromatography analysis, conversion
into the free ligand following UV irradiation was detected. The
caged TLR4 agonist was shown to induce p65 nuclear transloca-
tion and NF-kB-dependent transcriptional activity in cells only
after UV exposure. A first proof-of-principle for exerting spatial
control over immune activation was delivered with the caged
TLR4 ligand. Restricting UV irradiation, using a pinhole with an
area of 3.1 mm2, induced p65 nuclear translocation only in cells
within the pinhole area. Currently, UV-mediated photoexcitation
of TLR4-expressing cells has not been achieved with higher
spatial resolution. Further reduction of the area of photoactiva-
tion toward the order of sub-micrometer resolution would allow
biologists to extract information from activating TLRs at specific
subcellular compartments, which can lead to the induction of
distinct signaling pathways as discussed above. This level of
spatial control cannot be achieved by UV excitation alone, since
photons above and below the focal point, as well as scattered
photons outside of the focus beam, have the capacity to uncage
ligands.
One way to enable the assessment of TLR signaling from spe-
cific (sub)cellular sites, without further reducing the volume of
excitation, is to spatially restrict the photocaged ligands to the
specific site of interest. This has successfully been applied in a
chimeric receptor model, in which the erythropoietin (Epo) bind-
ing domain of the Epo receptor has been fused to the TIR-
signaling domain of TLR4 (Duc and Huse, 2015). A photocaged
Epo mimetic peptide (NVOC-EMP1) was immobilized on culture
dishes via a streptavidin-biotin linkage. This enabled activation
of the chimeric receptor specifically at the plasma membrane
upon UV irradiation. In this model stimulation of single cells, as
visualized by nuclear translocation of p65, was obtained using
a mosaic digital diaphragm system that allows decaging in a cir-
cle with a diameter of about 5 mm. To our knowledge this
approach of restricting ligands has not yet been applied to
TLR-specific ligands.
A different approach to obtain a higher level of spatial control is
the use of photocaging groups that are removable by two-
photon excitation (TPE). During TPE, two photons of infrared
(IR) light carrying roughly half the energy necessary to excite808 Cell Chemical Biology 24, July 20, 2017an electron from its ground state to its excited state are simulta-
neously absorbed (Palikaras and Tavernarakis, 2001). Two
different IR lasers are positioned perpendicular to the sample,
generating a focal point with a high radiation intensity. TPE
quadratically depends on light intensity, therefore IR photons
out of the focal point have almost no chance of exciting a photo-
caging group. Using this technique, the volume of excitation can
be reduced to 1 fL (Klán et al., 2013), roughly 2%of the volume of
a vesicle with a diameter of 1 mm. The prospect of uncaging
ligands within single, small, TLR-carrying vesicles is intriguing
and may add to the chemical toolbox available to study spatio-
temporal effects. An additional advantage of TPE is that the
use of less energetic IR photons reduces the potential for
inducing cytotoxic events, such as inducing DNA damage or
the generation of reactive oxygen species.
The photolytic efficiency of most NB derivatives used for one-
photon excitation is too low for TPE applications. The photolytic
efficiency can be enhanced by increasing the size of the conju-
gated system, the planarity of the cage, and the amount of strong
donor/acceptor couples (Bort et al., 2013). Such adjustments are
often paired with an increase in hydrophobicity, an unwanted
property for experiments performed under aqueous conditions.
This hurdle has held back the development of groups applicable
for TPE in biological experiments. To fill this gap,Momotake et al.
(2006) synthesized the nitrodibenzofuran (NDBF) group as an
alternative caging moiety with a high photolytic efficiency. The
NDBF group photolyzes 16–160 times faster than other NB de-
rivatives and is currently one of the most efficient NB-derived
photocages, competed with only by a recent improved version
of this photocage (Komori et al., 2016). The NBDF group has
already successfully been applied as a cage for iron (Kennedy
et al., 2010), nucleosides (Lusic et al., 2010), and inositol-1,4,5-
triphosphate (IP3) (Figure 5D) (Kantevari et al., 2012). These
combined results suggest that the use of two-photon uncaging
approaches could be an exciting prospect in conjunction with
caged TLR ligands to study the dynamics of TLR signaling
from specific (sub)cellular sites.
The Dynamics of Intracellular NA-Sensing TLRs
The NA-sensing TLRs, TLR3, TLR7, TLR8, and TLR9, signal
from intracellular vesicles along the endolysosomal pathway.
Despite this seemingly simple spatial organization, recent dis-
coveries indicate that TLR9, and possibly also TLR7 and TLR8,
induce signaling pathways that activate NF-kB and IRF7 from
functionally distinct intracellular vesicles (Figure 4B).
The first evidence that NA-sensing TLRs induce distinct sig-
nals depending on spatial context was obtained using two struc-
turally diverse synthetic TLR9 ligands: CpG-A and CpG-B oligo-
deoxynucleotides (ODNs). While mouse pDCs produce IFN-I in
response to multimeric CpG-A, monomeric CpG-B only induces
the release of pro-inflammatory cytokines (Honda et al., 2005).
The difference in cytokine output was proposed to rely on the
distinct intracellular trafficking properties of these ligands.
CpG-A was retained in early endosomes for a prolonged time,
while CpG-B rapidly translocated to late endosomes and lyso-
somes. A slow progression of CpG-A through the endolysoso-
mal pathway is specific for pDCs. In cDCs, the trafficking prop-
erties of CpG-A resemble those of CpG-B, and both ligands
induce pro-inflammatory cytokines. While not normally released
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with the liposomal transfection agent DOTAP. This reagent en-
hances endosomal retention of CpG-A.
Recently, an endosomal cargo trafficking pathway has been
identified as a critical regulator for inducing IFN-I expression
downstream of TLR9. Upon TLR9 stimulation in pDCs, the cargo
shuttling protein adaptor protein-3 (AP-3) mediated transloca-
tion of TLR9 from early endosomes to lysosome-related organ-
elles (LROs), and this was a prerequisite for the activation of
IRF7 (Sasai et al., 2010). Recruitment of AP-3 to TLR9-containing
vesicles depended on PIKfyve, an enzyme controlling phosphoi-
nositide (PI) metabolism (Shisheva, 2008). PI(3)P is found on
early endosomes and PIKfyve catalyzes its phosphorylation to
PI(3,5)P2, which is abundantly present on late endosomes (Cat-
imel et al., 2008). Inhibition of PIKfyve impaired the translocation
of TLR9 and CpG-A into LROs (Hayashi et al., 2015). In addition,
the production of IFN-I downstream of TLR9 was specifically
blocked by inhibiting PIKfyve in murine bone marrow-derived
DCs (BMDCs).
These combined data support a model in which TLR9 traffics
between functionally different endosome populations to induce
distinct signaling cascades. Remarkably, TLR7, TLR8, and TLR9
induce distinct signaling cascades to activate NF-kB and IRF7
using the same adaptor set consisting of TIRAP and MyD88
(Bonham et al., 2014). The mechanism by which different path-
ways can be induced using the same adaptors remains incom-
pletely understood. The observation that TLR9 drives IFN-I pro-
duction from LROs suggests that cellular factors, facilitating the
assembly of a signaling platform capable of activating IRF7, may
be restricted to these vesicles. TLR3 is different from other NA-
sensing TLRs in relying on TRIF, instead of TIRAP and MyD88,
for the activation of both NF-kB and IRFs (Brubaker et al., 2015).
Whether TLR3-induced signaling pathways also depend on
spatial context awaits further evaluation.
Caging Strategies for NA-Sensing TLRs
Recent efforts to conditionally control the activation of NA-
sensing TLRs using UV light as an external trigger encompass
the development of photocaged ligands for TLR7, TLR8, and
TLR9. Based on the crystallographic data mentioned above,
the C4 amine of the dual TLR7 and TLR8 agonist resiquimod
was suggested to be critical for its activity (Zhang et al.,
2016b). Thus, an NPPOC group was introduced at this position,
rendering the ligand inactive (Ryu et al., 2014) (Figure 6A). A
mouse macrophage cell line with an NF-kB reporter (RAW-
Blue) was used to confirm that the product of UV-irradiated
NPPOC-resiquimod induced TLR7 and TLR8 activation. In addi-
tion, BMDCs treated with the photocaged ligands secreted the
cytokines IL-6, IL-12, and TNF-a only after UV irradiation.
Another imidazoquinoline, the TLR7-specific agonist imiquimod,
was successfully caged in a similar manner.
For TLR9, several CpG ODNs were synthesized carrying
the photocage nitropiperonyloxymethyl, by incorporating pre-
protected thymidine phosphoramidite building blocks (Govan
et al., 2015) (Figure 6B). These thymidine residues were either
equally distributed over theODN or concentrated at both termini.
Both caging strategies prevented activation of TLR9 in the
Burkitt’s lymphoma cell line Namalwa, yet a more pronounced
photoactivation for the ODN with terminally protected thymidineresidues was observed bymeasuring IL-6 secretion. The authors
hypothesized that the central section of this ligand may be
able to bind TLR9 without inducing activation, analogous to
the above-discussed photocaged TLR2 ligand. Whether caged
CpG ODN is able to create a pre-existing pool of agonist-bound
TLR9 awaits further investigation.
Currently, one of the major limitations of using light-activated
caging reagents is the level of spatial precision that can be
achieved. As discussed above, two-photon uncaging ap-
proaches may further reduce the volume of excitation, allowing
TLR ligands to be activated within single specific endosomes.
Another recently emerged field of chemistry, which might be of
great use here, exploits bio-orthogonal chemical uncaging strate-
gies (Li and Chen, 2016). Chemical cages, such as azides, can be
removed using a Staudinger reduction reaction and have previ-
ously been used to cage peptide epitopes (Pawlak et al., 2015)
and catalytic sites in enzymes (Luo et al., 2016). In terms of uncag-
ing rates and yields, the most promising chemical cages are
trans-cyclooctene cages (Fan et al., 2016). These were used
initially to allow triggered drug release from antibody-drug conju-
gations (Versteegen et al., 2013; Rossin et al., 2016), but have also
been used to cage enzyme activities (Li et al., 2014; Zhang et al.,
2016a). Although none of these chemical caging strategies have
been applied on TLR ligands yet, they may prove to yield useful
tools for the localized activation of TLRs by directing chemical
uncaging agents to specific (sub)cellular sites.Outlook
The previous static model of TLR signaling has undergone major
revisions in recent years. It has become evident that TLR
signaling is regulated dynamically within cells, where the specific
subcellular localization and timing of TLR activation affect
signaling outcome. New reagents, techniques, and chemistries
are appearing fast, allowing spatial and temporal control over
TLR activation. These chemicals are expected to become valu-
able tools for delineating the complex dynamic nature of TLR
signaling. Controlled activation of TLRs is essential for potent
antimicrobial immune responses. At the same time, undesired
TLR signaling may induce deleterious immune responses in the
case of misregulation or overactivation toward infection, or auto-
immunity toward self-agonists. A better understanding of the dy-
namic cellular processes that regulate TLR signaling will guide
the rational design of novel therapeutics to effectively prevent
these instances of immune pathogenesis.ACKNOWLEDGMENTS
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